Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients

CM Chen, YR Wu, ML Cheng, JL Liu, YM Lee… - Biochemical and …, 2007 - Elsevier
CM Chen, YR Wu, ML Cheng, JL Liu, YM Lee, PW Lee, BW Soong, DTY Chiu
Biochemical and biophysical research communications, 2007Elsevier
Increased oxidative stress and mitochondrial abnormalities contribute to neuronal
dysfunction in Huntington's disease (HD). We investigated whether these pathological
changes in HD brains may also be present in peripheral tissues. Leukocyte 8-
hydroxydeoxyguanosine (8-OHdG) and plasma malondialdehyde (MDA) were elevated, and
activities of erythrocyte Cu/Zn-superoxide dismutase (Cu/Zn-SOD) and glutathione
peroxidase (GPx) reduced in 16 HD patients when compared to 36 age-and gender …
Increased oxidative stress and mitochondrial abnormalities contribute to neuronal dysfunction in Huntington’s disease (HD). We investigated whether these pathological changes in HD brains may also be present in peripheral tissues. Leukocyte 8-hydroxydeoxyguanosine (8-OHdG) and plasma malondialdehyde (MDA) were elevated, and activities of erythrocyte Cu/Zn-superoxide dismutase (Cu/Zn-SOD) and glutathione peroxidase (GPx) reduced in 16 HD patients when compared to 36 age- and gender-matched controls. Deleted and total mitochondrial DNA (mtDNA) copy numbers were increased, whereas the mRNA expression levels of mtDNA-encoded mitochondrial enzymes are not elevated in HD leukocytes compared to the normal controls. Plasma MDA levels also significantly correlated with HD disease severity. These results indicate means to suppress oxidative damage or to restore mitochondrial functions may be beneficial to HD patients. Plasma MDA may be used as a potential biomarker to test treatment efficacy in the future, if confirmed in a larger, longitudinal study.
Elsevier